Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
Abstract Background The development of Bruton’s tyrosine kinase inhibitors (BTKi) for the treatment of chronic lymphocytic leukaemia (CLL) has provided a highly effective and relatively non-toxic alternative to conventional chemotherapy. Some studies have shown that BTKi can also lead to improvement...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
BMC
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/72b9726b70ce4860bc6b28377c17d44e |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|